News

New Drug Implant Technology Offers Complete Infection Protection and Peace of Mind to Patients

(Durham, NC) – Zymeron Corporation, a research-based biotechnology company, announced that it received multi-year funding from the Department of Defense to continue its development of a long-lasting antimalaria prophylactic drug.

Rapid Point-of-Care Test Developed as a Decision-Making Tool for Dengue Vaccination

(Durham, NC) – Zymeron Corporation, a research-based biotechnology company, announced that it develops a rapid point-of-care test (POCT) as a decision-making diagnostic tool to determine the benefit-risk of Dengue vaccination strategies. The test was validated with a cohort of clinical samples with greater than 99% sensitivity and specificity.

Zymeron Received Award from the NIH to Develop Rapid Point-of-Care Tests

(Durham, NC) – Zymeron Corporation, a research-based biotechnology company, announced that it received a three-year, SBIR Phase II award from the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH) to develop rapid point-of-care diagnostic tests to detect serologic status of individuals for cytomegalovirus (CMV) infection.

Zymeron Relocated to the Frontier Campus, Research Triangle Park

(Durham, NC) – Zymeron Corporation, a research-based biotechnology company, announced that it is relocated to the Frontier Campus Building 400, Research Triangle Park, NC. Frontier Building 400 provides renovated dynamic laboratory spaces for start-ups and small size companies with up to 50 employees.